AR039629A1 - Antagonistas de proteinas mcp - Google Patents

Antagonistas de proteinas mcp

Info

Publication number
AR039629A1
AR039629A1 ARP030101253A ARP030101253A AR039629A1 AR 039629 A1 AR039629 A1 AR 039629A1 AR P030101253 A ARP030101253 A AR P030101253A AR P030101253 A ARP030101253 A AR P030101253A AR 039629 A1 AR039629 A1 AR 039629A1
Authority
AR
Argentina
Prior art keywords
mcp
protein
protein antagonists
mutants
proteins
Prior art date
Application number
ARP030101253A
Other languages
English (en)
Original Assignee
Applied Research Systems
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems, Univ California filed Critical Applied Research Systems
Publication of AR039629A1 publication Critical patent/AR039629A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Antagonistas novedosos de proteínas MCP, en particular de proteína MCP-1, pueden ser obtenidos generando mutantes MCP en los cuales al menos un sitio de unión GAG ubicado en la terminal-N de proteínas MCP es eliminado siguiendo sustituciones no conservativas. Los compuestos preparados de acuerdo con la presente invención pueden utilizarse en el tratamiento o prevención de enfermedades relacionadas con una actividad indeseable de proteínas MCP, tal como enfermedad inflamatoria, enfermedades autoinmunes, enfermedades vasculares, y cáncer. Reivindicación 1: antagonistas de proteínas MCP que consisten de mutantes de proteínas MCP en las cuales las siguientes combinaciones de residuos, numeradas en la secuencia de MCP-1 madura humana, son sustituidas a Alanina, Glicina, Serina, Treonina, Prolina, ácido Aspártico, ácido Glutámico, o Glutamina: a- 18 y 19; b- 18 y/o 19, junto con 58; c- 18 y/o 19, junto con 66; d-18 y/o 19, junto con 58 y 66; e- 18 y/o 19, junto con uno o más de los siguientes: 24, 44, 49, 75.
ARP030101253A 2002-04-10 2003-04-09 Antagonistas de proteinas mcp AR039629A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37144202P 2002-04-10 2002-04-10

Publications (1)

Publication Number Publication Date
AR039629A1 true AR039629A1 (es) 2005-03-02

Family

ID=28792054

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101253A AR039629A1 (es) 2002-04-10 2003-04-09 Antagonistas de proteinas mcp

Country Status (18)

Country Link
US (1) US7425324B2 (es)
EP (1) EP1495050A1 (es)
JP (1) JP2006505243A (es)
KR (1) KR20040101426A (es)
CN (1) CN1665839A (es)
AR (1) AR039629A1 (es)
AU (1) AU2003240765A1 (es)
BR (1) BR0309238A (es)
CA (1) CA2509767A1 (es)
EA (1) EA200401342A1 (es)
HR (1) HRP20040946A2 (es)
IL (1) IL164464A0 (es)
MX (1) MXPA04009874A (es)
NO (1) NO20044850L (es)
PL (1) PL373007A1 (es)
RS (1) RS89104A (es)
WO (1) WO2003084993A1 (es)
ZA (1) ZA200409062B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR046594A1 (es) * 2003-10-16 2005-12-14 Applied Research Systems Usos terapeuticos de variantes de quemoquina
US20050232923A1 (en) * 2003-11-05 2005-10-20 Li Yan Methods and compositions for treating MCP-1 related pathologies
US20050106740A1 (en) * 2003-11-13 2005-05-19 Boyes Barry E. Methods, systems and devices for performing analytical protocols
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
CA2618951A1 (en) 2005-08-12 2007-02-22 Schering Corporation Mcp1 fusions
EP2041568A4 (en) * 2006-06-15 2009-08-12 CCR2 ANTAGONISTS FOR CHRONIC BREATHING REACTIONS IN ORGAN TRANSPLANTATIONS
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
EP2042516A1 (en) 2007-09-27 2009-04-01 Protaffin Biotechnologie AG Glycosaminoglycan-antagonising MCP-1 mutants and methods of using same
EP2391645A1 (en) 2009-01-30 2011-12-07 Protaffin Biotechnologie AG Glycosaminoglycan-antagonising mcp-i mutants and methods of using same
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
KR101238196B1 (ko) * 2010-12-16 2013-02-28 사회복지법인 삼성생명공익재단 대장암의 간 전이 진단용 조성물 및 그 용도
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins

Also Published As

Publication number Publication date
AU2003240765A1 (en) 2003-10-20
CN1665839A (zh) 2005-09-07
BR0309238A (pt) 2005-02-15
US20070004906A1 (en) 2007-01-04
ZA200409062B (en) 2005-11-09
HRP20040946A2 (en) 2005-06-30
WO2003084993A1 (en) 2003-10-16
MXPA04009874A (es) 2005-10-19
EP1495050A1 (en) 2005-01-12
JP2006505243A (ja) 2006-02-16
EA200401342A1 (ru) 2005-08-25
US7425324B2 (en) 2008-09-16
NO20044850L (no) 2004-12-09
KR20040101426A (ko) 2004-12-02
PL373007A1 (en) 2005-08-08
CA2509767A1 (en) 2003-10-16
IL164464A0 (en) 2005-12-18
RS89104A (en) 2006-12-15

Similar Documents

Publication Publication Date Title
AR039629A1 (es) Antagonistas de proteinas mcp
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
EA200400971A1 (ru) Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения
ATE550031T1 (de) Zusammensetzungen und verfahren für die lipomodellierung
DK1448564T3 (da) Substituerede indolizinlignende forbindelser og fremgangsmåder til anvendelse
DK1464639T3 (da) Ravsyrerester af probucol til inhibering af ekspressionen af VCAM-1
SG196821A1 (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
EP1539228A4 (en) NEW COMPOSITION AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES
CY1106799T1 (el) Ανταγωνιστες των cxcr3-συνδεσης cxc χημειοκινων
BRPI0811320A2 (pt) Surfactantes reconstituídos com propriedades melhoradas
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
EA200000379A1 (ru) Усеченные по амино-концу rantes как антагонисты хемокинов
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
RU2014131605A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
DE69231918D1 (de) Peptidantagonisten des bradykinin
EA200501550A1 (ru) СВЯЗАННЫЕ С МАТРИЦЕЙ ПЕПТИДОМИМЕТИКИ β-ШПИЛЕЧНОЙ СТРУКТУРЫ С АКТИВНОСТЬЮ АНТАГОНИСТОВ CXCR4
EA200701599A1 (ru) Способ и композиция для восстановления сердечной ткани
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
DK384084A (da) Vaeksthormonfrigoerende peptider samt fremgangsmaade til behandling af pattedyr hermed
RU2011110459A (ru) Рекомбинантно полученный человеческий фактор viii и ix
EA200600996A1 (ru) Композиция для полезного воздействия на кожу с использованием ключевых промежуточных продуктов клеточного метаболизма
CN110506050A (zh) γC细胞因子活性的稳定调节剂
ATE402958T1 (de) Antagonisten des ige-rezeptors
EA200801077A1 (ru) Антагонисты взаимодействия pf4 и rantes

Legal Events

Date Code Title Description
FB Suspension of granting procedure